Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Kathy Dominy, Matthew Salmon, Richard Szydlo, Chloe Hayden, Helen E White, Mary Alikian, Dragana Milojkovic, Mhairi Copland, Letizia Foroni, Nicholas C.P. Cross, Richard E Clark, Jane F. Apperley

Blood (2022) 140 (Supplement 1): 9631–9632.

https://doi.org/10.1182/blood-2022-170375

Published: 2022

Journal Articles

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian, Rebecca Ellwood, Olga Tatarinova, Graham David Rose, George Nteliopoulos, Gareth Gerrard, Jamshid S Khorashad, MD PhD, Dragana Milojkovic, MBBS, PhD, Alistair Reid, BSc, PhD, Letizia Foroni, MD PhD, Richard Clark, MBBS, MRCP, MRCPath, MD, Jane Apperley, MB ChB MD

Blood (2018) 132 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2018-99-117616

Published: 2018

Journal Articles

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Simone Claudiani, MD, Adi Shacham Abulafia, Ira Sabli, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1628.

https://doi.org/10.1182/blood.V130.Suppl_1.1628.1628

Published: 2017

Journal Articles

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

Simone Claudiani, MD, Aoife Gatenby, BSc, Richard Szydlo, PhD, Dragana Milojkovic, MBBS, PhD, Emily Ching, George Nesr, MD, Renuka Palanicawander, MD, George Nteliopoulos, Mary Alikian, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Jane F. Apperley, FRCP, FRCPath, MD MBChB

Blood (2017) 130 (Supplement 1): 1629.

https://doi.org/10.1182/blood.V130.Suppl_1.1629.1629

Published: 2017

Journal Articles

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Mary Alikian, MSc, PhD, Alexandra S. Whale, Simon Cowen, Kim Piechocki, Michael John Griffiths, BSc, Alistair G Reid, BSc, PhD, Susanna Akiki, Jane F. Apperley, MD, Jim F. Huggett, Letizia Foroni

Blood (2016) 128 (22): 3104.

https://doi.org/10.1182/blood.V128.22.3104.3104

Published: 2016

Journal Articles

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

Georgios Nteliopoulos, MSc, PhD, Alexandra Bazeos, MB, BS, MRCP, Gareth Gerrard, PhD, Simone Claudiani, MD, Ed Curry, PhD, Mary Alikian, MSc, PhD, Hui En Foong, Letizia Foroni, MD PhD FRCPath, Jane F. Apperley, MD

Blood (2016) 128 (22): 1223.

https://doi.org/10.1182/blood.V128.22.1223.1223

Published: 2016

Journal Articles

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Mary Alikian, Peter Ellery, Matrin Forbes, Gareth Gerrard, PhD, Tim Aitman, Dalia Kasperaviciute, Dragana Milojkovic, PhD, David Marin, MD, John M Goldman, MD, Jane F Apperley, MD, Letizia Foroni, MD, Alistair Reid, PhD

Blood (2013) 122 (21): 4006.

https://doi.org/10.1182/blood.V122.21.4006.4006

Published: 2013

Journal Articles

Targeted High-Throughput Sequencing For The Detection Of Mutations Associated With Myeloproliferative Neoplasms

Ferrari Robin, BSc, Sakuntala Ale, Aysha Patel, BSc, Mikel Valgañón, PhD, Hui En Foong, MSc, Mary Alikian, Kikkeri Naresh, Dragana Milojkovic, PhD, Jane F Apperley, MD, Letizia Foroni, MD, Gareth Gerrard, PhD

Blood (2013) 122 (21): 1613.

https://doi.org/10.1182/blood.V122.21.1613.1613

Published: 2013

Journal Articles

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

Blood (2013) 122 (21): 3824.

https://doi.org/10.1182/blood.V122.21.3824.3824

Published: 2013

Journal Articles

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Blood (2013) 122 (21): 743.

https://doi.org/10.1182/blood.V122.21.743.743

Published: 2013

Journal Articles

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Blood (2013) 121 (3): 489–498.

https://doi.org/10.1182/blood-2012-05-431379

Published: 2013

Includes: Supplemental data

Journal Articles

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

Jacob Grinfeld, Juan M Alonso-Dominguez, Mary Alikian, Mikel Valgañón, PhD, Georgios Nteliopoulos, PhD, Deborah L. White, PhD, FFSc(RCPA), David Marin, Corinne Hedgley, Stephen O'Brien, Richard E. Clark, MD, Richard M Szydlo, Jane Apperley, John M Goldman, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 2555.

https://doi.org/10.1182/blood.V120.21.2555.2555

Published: 2012

Journal Articles

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

Juan M. Alonso-Dominguez, Sr., MD, Jacob Grinfeld, MD, Mary Alikian, David Marin, Alistair Reid, PhD, Mustafa Daghistani, Jane Apperley, John M Goldman, MD, Corinne Hedgley, Steve O‘Brien, Richard E. Clark, MD, Letizia Foroni, Gareth Gerrard, PhD

Blood (2012) 120 (21): 875.

https://doi.org/10.1182/blood.V120.21.875.875

Published: 2012

Journal Articles

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Dragana Milojkovic, MD, Gareth Gerrard, PhD, Christos Paliompeis, Marco Bua, MD, Alistair Reid, PhD, Mary Alikian, Jamshid Khorashad, MD, PhD, John M Goldman, David Marin, Letizia Foroni, MD PhD, Jane F Apperley, MBChB, MD, FRCP, FRCPath

Blood (2011) 118 (21): 605.

https://doi.org/10.1182/blood.V118.21.605.605

Published: 2011

NARROW

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

10-Year Outcome of Chronic Myeloid Leukemia Patients Resistant to Frontline Imatinib

Identification of a 'Safe Haven' for RT-qPCR Responses in CML: Can We Reduce the Frequency of Molecular Monitoring?

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia

Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy

NGS-Assisted DNA-Based Digital qPCR Facilitates Stratification Of CML Patients In Long-Term Molecular Remission Based On The Presence Of Detectable BCR-ABL1 DNA

Targeted High-Throughput Sequencing For The Detection Of Mutations Associated With Myeloproliferative Neoplasms

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.

PTCH1 Expression At Diagnosis Reliably Predicts Treatment Failure in Imatinib-Treated Chronic Myeloid Leukaemia Patients

The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only